Article Text

Download PDFPDF

Precision immunophenotyping by high-throughput TCR sequencing in human glioma
  1. Jennifer Sims1,
  2. Boris Grinshpun2,
  3. Yaping Feng3,
  4. Timothy Ung4,
  5. Justin Neira1,
  6. Jorge Samanamud1,
  7. Peter Canoll5,
  8. Yufeng Shen2,
  9. Peter Sims2 and
  10. Jeffrey Bruce1
  1. Aff1 grid.21729.3f0000000419368729Dept. of Neurological SurgeryColumbia University New York NY USA
  2. Aff2 grid.21729.3f0000000419368729Dept. of Systems BiologyColumbia University New York NY USA
  3. Aff3 grid.430387.b0000000419368796Waksman InstituteRutgers University New Brunswick NJ USA
  4. Aff4 grid.241116.10000000107903411School of MedicineUniversity of Colorado Denver, Aurora CO USA
  5. Aff5 grid.21729.3f0000000419368729Dept. of Pathology & Cell BiologyColumbia University New York NY USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Immunotherapy for glioblastoma (GBM) is the subject of numerous clinical trials, given the potential for the adaptive immune response to combat this diffusely infiltrating tumor. However, rational application of immunotherapy to these tumors is challenging because of the peculiar immune privilege of the brain and the molecular heterogeneity of glioma antigens. Little is known about patient-to-patient variability in the potential to generate anti-glioma immune responses of their systemic and local T cell populations.

We conducted a foundational study of the population-wide characteristics of both the peripheral blood and local, tissue-infiltrating T lymphocytes (TILs) of glioma patients using TCRseq. Through reverse transcription and pan-repertoire amplification of the TCR-alpha and -beta chains we generated TCRseq libraries from matched surgical tissue and peripheral blood cells. Using peripheral blood samples from primary GBM, low-grade glioma, and non-tumor patients (N=14), we define new immunophenotypes using statistical metrics based on information theory – specifically, the clonality associated with antigen-binding function in the TCRs of TIL, and the antigen-binding associated divergence of the TIL population from the blood. We found that diversification of this repertoire was characteristic of high-grade tumors, and correlated strongly with the activation of specific immune and inflammatory pathways. Furthermore, we found strong correlation between usage of a subset of TCR sequences in patients' peripheral blood and the divergence of their TIL population from the peripheral repertoire. We anticipate that these immunophenotypes will be key to monitoring and predicting response to anti-glioma vaccines and immunotherapy, and understanding the immunological mechanisms determining their efficacy.